Evidence map›Paper›PMID 42538472›Full record

SynthesisJournal of neurology2026

Central nervous system histopathological findings in classic infantile Pompe disease: a systematic review with clinical relevance.

Jan J A van den Dorpel, Martha C Faraguna, Robert M Verdijk, Nadine A M E van der Beek, W W M Pim Pijnappel, Ans T van der Ploeg, Johanna M P van den Hout

Abstract readSystematic Review
In one paragraph

Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jan J A van den Dorpel *Center for Lysosomal and Metabolic Diseases, Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2060, 3000 CB, Rotterdam, The Netherlands.
Martha C Faraguna *Center for Lysosomal and Metabolic Diseases, Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2060, 3000 CB, Rotterdam, The Netherlands.
Robert M VerdijkDepartment of Pathology, Section Neuropathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Nadine A M E van der BeekCenter for Lysosomal and Metabolic Diseases, Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
W W M Pim PijnappelCenter for Lysosomal and Metabolic Diseases, Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2060, 3000 CB, Rotterdam, The Netherlands.
Ans T van der PloegCenter for Lysosomal and Metabolic Diseases, Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2060, 3000 CB, Rotterdam, The Netherlands.
Johanna M P van den HoutCenter for Lysosomal and Metabolic Diseases, Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2060, 3000 CB, Rotterdam, The Netherlands. j.vandenhout@erasmusmc.nl.ORCID http://orcid.org/0000-0001-8091-263X

Funding

LSH-TKI LSHM16008Prinses Beatrix Spierfonds W.TR19-02
6 · The paper itself

Abstract

introductionClassic infantile Pompe disease is the most severe phenotype within the clinical spectrum of Pompe disease and is characterized by central nervous system (CNS) involvement.

methodsA systematic review on histopathological findings in classic infantile Pompe disease was conducted using Embase, Medline Ovid, Web of science and Cochrane central databases for original research articles until 16-12-2025. Articles reporting a histological examination of the CNS were selected. Classic infantile Pompe disease was defined by hypertrophic cardiomyopathy, symptom onset < 12 months of age, and GAA deficiency, if available.

resultsOf the 3734 records identified, 39 articles were included in the study, comprising 49 patients, 7 of whom treated with enzyme replacement therapy. The median age at autopsy was 6 months (range 1.2-17.0) for untreated and 12 months (range 7.5-21.0) for treated patients. Histologic abnormalities were found throughout the CNS. The cerebral and cerebellar white matter (WM), globus pallidus, dentate nucleus, motor nuclei of the brainstem, and anterior horn cells were most frequently affected. Glycogen accumulation was severe in astrocytes and in neurons of the globus pallidus. Cortical neurons were affected with greater variability, and subcortical structures were more frequently involved than cortical ones.

conclusionsUnderstanding of CNS involvement in classic infantile Pompe disease is rapidly evolving. Histopathological studies from children up to 21 months demonstrate early and widespread CNS pathology. Notably, there is a marked temporal gap between the extensive abnormalities observed at autopsy in infancy and later radiological, biochemical, and clinical manifestations. While white matter pathology is already prominent in young patients, abnormalities on magnetic resonance imaging typically emerge from 2 to 3 years of age, biomarker changes from around 5 years, and cognitive decline, reduced processing speed, and background activity slowing on electroencephalogram from approximately 8-10 years onward. These observations suggest a gradual evolution of CNS disease, although direct clinicopathological correlations remain limited. Epilepsy has been reported later in the disease course, and we have observed upper motor neuron signs in older patients, suggesting progressive gray and white matter involvement that may contribute to cognitive decline. The mechanisms linking glycogen accumulation to neurological manifestations remain incompletely understood. Taken together, these observations form the basis for several hypotheses on the pathogenesis of CNS involvement in classic infantile Pompe disease.

Indexed as

BrainGlycogen Storage Disease Type IIHumansInfantAstrocytesBrain glycogenCentral nervous systemClassic infantile Pompe diseaseGray matter diseaseLong-term survivorsWhite matter abnormalities

Identifiers

PMID42538472
PMCPMC13427966

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.